Curanex Pharmaceuticals Inc
0.7144-0.05 (-6%)
Oct 29, 4:00:01 PM EDT · NasdaqCM · CURX · USD
Key Stats
Market Cap
20.25MP/E (TTM)
-Basic EPS (TTM)
-0.02Dividend Yield
0%Recent Filings
8-K
Debt repaid, shares issued
Curanex Pharmaceuticals issued 28,312 shares of common stock to investor Xiaohong Song on September 25, 2025, fulfilling a $200,000 subscription from November 2024 post-IPO, representing 0.1% of outstanding shares under a Section 4(a)(2) exemption. The company prepaid $408,537.32 to settle two $200,000 promissory notes from CEO's wife Dian Ying Jing, wiping out all outstanding debt and avoiding $26,182.68 in future interest. Debt cleared. This bolsters the balance sheet after the August IPO.
8-K
IPO over-allotment exercised
Curanex Pharmaceuticals announced the full exercise of its underwriters' over-allotment option on September 12, 2025, selling 562,500 additional shares at $4.00 each for $2.25 million in gross proceeds. This boosts the IPO total to $17.25 million before expenses, with 28,312,500 common shares now outstanding. Funds will fuel Phyto-N's advancement through FDA studies and Phase I trials for ulcerative colitis. Yet risks loom in clinical uncertainties.
10-Q
Q2 FY2025 results
Curanex Pharmaceuticals posted a Q2 net loss of $60,346, up 36.6% y/y from $44,200, driven by higher general and administrative expenses of $57,658 versus $44,200 last year, while operating cash burn hit $440,029 for the half-year (derived). No revenue yet, as the biotech focuses on preclinical botanical drug development for inflammatory diseases like ulcerative colitis. Cash dipped to $108,862 by quarter-end, offset by $400,000 in shareholder loans at 4.34% maturing 2027, but the August 27, 2025 IPO delivered $12.9M net proceeds to fuel Phyto-N studies and IND filing. Lease costs added modestly to expenses. Controls faltered. Competition in drug development looms large.
8-K
IPO closes with $15M proceeds
Curanex Pharmaceuticals closed its initial public offering on August 27, 2025, selling 3,750,000 shares at $4.00 each for gross proceeds of $15 million and net proceeds of approximately $12.1 million. The funds will advance its lead botanical drug Phyto-N through FDA studies, IND submission, and Phase I trials for ulcerative colitis and other inflammatory diseases. Underwriters hold a 45-day option for 562,500 more shares. Trading began on Nasdaq under CURX.
8-K
Curanex IPO prices at $4/share
Curanex Pharmaceuticals priced its initial public offering on August 25, 2025, selling 3,750,000 shares at $4.00 each for $15 million in gross proceeds, with an option for underwriters to buy 562,500 more shares. The deal closes August 27, netting about $12.1 million after fees. Funds will advance Phyto-N, the lead botanical drug for ulcerative colitis, through FDA toxicology studies, IND filing, and early trials. Trading starts today on Nasdaq as CURX. Yet risks loom in forward-looking plans.
ACXP
Acurx Pharmaceuticals, Inc.
5.68-0.62
CNBX
CNBX Pharmaceuticals Inc.
0.00+0.00
CNTB
Connect Biopharma Holdings Limi
1.58+0.04
CPMD
Cannapharmarx Inc.
0.01+0.00
CUBT
CURATIVE BIOTECHNOLOGY INC.
0.01-0.00
IMA
ImageneBio, Inc.
8.79+0.09
NXEN
Nexien BioPharma, Inc.
0.01+0.00
TRML
Tourmaline Bio, Inc.
47.98+47.98
TTNP
Titan Pharmaceuticals, Inc.
4.61-0.18
XCUR
Exicure, Inc.
4.46-0.09